193 related articles for article (PubMed ID: 37833915)
1. Uncovering NOTCH1 as a Promising Target in the Treatment of
Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
[No Abstract] [Full Text] [Related]
2. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
3. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.
Wang F; Wu P; Gong S; Chen Y; Gao J; Wang S; Shen Q; Tao H; Hua F; Zhou Z; Zou Z; Ma T; Jia Y
Cell Signal; 2020 Aug; 72():109643. PubMed ID: 32320859
[TBL] [Abstract][Full Text] [Related]
4. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
5. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
[TBL] [Abstract][Full Text] [Related]
6. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
[TBL] [Abstract][Full Text] [Related]
7. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
9. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Grey W; Ivey A; Milne TA; Haferlach T; Grimwade D; Uhlmann F; Voisset E; Yu V
Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):105-116. PubMed ID: 28939057
[TBL] [Abstract][Full Text] [Related]
10. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
11. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
14. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
Albouhair S; Morgado E; Lavau C
PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
16. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
17. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
18. MAT2A as Key Regulator and Therapeutic Target in
Secker KA; Bloechl B; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Jeong J; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456310
[TBL] [Abstract][Full Text] [Related]
19. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
[TBL] [Abstract][Full Text] [Related]
20. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
